Your browser doesn't support javascript.
loading
A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain, Ruth; Choi, Meena; Martin de la Fuente, Laura; Oehl, Kathrin; Chang, Ching-Yun; Zimmermann, Anne-Kathrin; Malander, Susanne; Olsson, Håkan; Surinova, Silvia; Clough, Timothy; Heinzelmann-Schwarz, Viola; Wild, Peter J; Dinulescu, Daniela M; Niméus, Emma; Vitek, Olga; Aebersold, Ruedi.
Affiliation
  • Hüttenhain R; ‡Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland. Electronic address: ruth.huttenhain@ucsf.edu.
  • Choi M; §Khoury College of Computer Sciences, Northeastern University, Boston, MA.
  • Martin de la Fuente L; ¶Department of Surgery and Oncology, Clinical Sciences, Lund University, Lund, Sweden.
  • Oehl K; ‖Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Chang CY; **Department of Statistics, Purdue University, West Lafayette, IN.
  • Zimmermann AK; ‖Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Malander S; ¶Department of Surgery and Oncology, Clinical Sciences, Lund University, Lund, Sweden.
  • Olsson H; ¶Department of Surgery and Oncology, Clinical Sciences, Lund University, Lund, Sweden.
  • Surinova S; ‡Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland.
  • Clough T; **Department of Statistics, Purdue University, West Lafayette, IN.
  • Heinzelmann-Schwarz V; ‡‡Gynecological Cancer Center, University Hospital Basel, University of Basel, Basel, Switzerland; §§Ovarian Cancer Research, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Wild PJ; ¶¶Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany.
  • Dinulescu DM; ‖‖Department of Pathology, Division of Women's and Perinatal Pathology Brigham and Women's Hospital Harvard Medical School, Boston, MA.
  • Niméus E; ¶Department of Surgery and Oncology, Clinical Sciences, Lund University, Lund, Sweden; ‡‡‡Department of Surgery, Skånes University hospital, Lund, Sweden.
  • Vitek O; §Khoury College of Computer Sciences, Northeastern University, Boston, MA; **Department of Statistics, Purdue University, West Lafayette, IN.
  • Aebersold R; ‡Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland; §§§Faculty of Science, University of Zurich, 8057 Zurich, Switzerland.
Mol Cell Proteomics ; 18(9): 1836-1850, 2019 09.
Article in En | MEDLINE | ID: mdl-31289117
ABSTRACT
Protein biomarkers for epithelial ovarian cancer are critical for the early detection of the cancer to improve patient prognosis and for the clinical management of the disease to monitor treatment response and to detect recurrences. Unfortunately, the discovery of protein biomarkers is hampered by the limited availability of reliable and sensitive assays needed for the reproducible quantification of proteins in complex biological matrices such as blood plasma. In recent years, targeted mass spectrometry, exemplified by selected reaction monitoring (SRM) has emerged as a method, capable of overcoming this limitation. Here, we present a comprehensive SRM-based strategy for developing plasma-based protein biomarkers for epithelial ovarian cancer and illustrate how the SRM platform, when combined with rigorous experimental design and statistical analysis, can result in detection of predictive analytes.Our biomarker development strategy first involved a discovery-driven proteomic effort to derive potential N-glycoprotein biomarker candidates for plasma-based detection of human ovarian cancer from a genetically engineered mouse model of endometrioid ovarian cancer, which accurately recapitulates the human disease. Next, 65 candidate markers selected from proteins of different abundance in the discovery dataset were reproducibly quantified with SRM assays across a large cohort of over 200 plasma samples from ovarian cancer patients and healthy controls. Finally, these measurements were used to derive a 5-protein signature for distinguishing individuals with epithelial ovarian cancer from healthy controls. The sensitivity of the candidate biomarker signature in combination with CA125 ELISA-based measurements currently used in clinic, exceeded that of CA125 ELISA-based measurements alone. The SRM-based strategy in this study is broadly applicable. It can be used in any study that requires accurate and reproducible quantification of selected proteins in a high-throughput and multiplexed fashion.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Mass Spectrometry / Biomarkers, Tumor / Proteomics / Carcinoma, Ovarian Epithelial Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cell Proteomics Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2019 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Mass Spectrometry / Biomarkers, Tumor / Proteomics / Carcinoma, Ovarian Epithelial Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cell Proteomics Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2019 Type: Article